Track the Everest Medicines Ltd. stock price and the full insider trade history of the company, a listed equity based in Hong Kong. Shares trade on HK HK, under the supervision of HKEX. Operating in the Health Care sector, Everest Medicines Ltd. has logged 18 reports. Market capitalisation: €10.1bn. The latest transaction was reported on 23 June 2026 (Purchase). Among the most active insiders: FU WEI. All data is free.
18
Insider Decl.
0
Thresholds
€126m
16 ops.
Buy Volume
·
0 ops.
Sell Volume
36Σ signal
Buys €126m· Sells
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental score
Ranked 20,712 of 26,176 companies
31.3
score / 100
Value
24
Quality
39
FCF yld-4.5%
Earn yld-3.0%
EV/EBITDA·
ROE-6.4%
Gross mgn69%
Net mgn-17%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Everest Medicines Ltd. is a biopharmaceutical company focused on developing innovative treatments for serious diseases in Asia. The company is listed on the Hong Kong Stock Exchange.
